Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.

ABSTRACT:

Background

Pembrolizumab plus chemotherapy (Pembrolizumab-CT) has been suggested as first-line treatment over pembrolizumab alone in aggressive non-small-cell lung cancer (NSCLC) with ⩾50% PDL1, but studies comparing these two strategies are lacking.

Objectives

To compare overall survival under pembrolizumab and Pembrolizumab-CT depending on tumor aggressiveness in PDL1 ⩾50% advanced NSCLC patients.

Design

A multicenter retrospective study was conducted of all patients with advanced NSCLC, PDL1 ⩾50% and ECOG 0-1, who received pembrolizumab or Pembrolizumab-CT as first-line treatment.

Methods

Tumor aggressiveness was defined as a sum of longest diameters (SLD) ⩾ 100 mm, a largest lesion diameter (LLD) >60 mm, ECOG 1, or need for corticosteroid therapy. Overall s

SUBMITTER: Lejeune M 

PROVIDER: S-EPMC12665830 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature